Abstract
Lesch-Nyhan syndrome (LNS) is a rare X-linked disorder caused by mutations in HPRT1, an important enzyme in the purine salvage pathway. Symptoms of LNS include dystonia, gout, intellectual disability, and self-mutilation. Despite having been characterized over 50 years ago, it remains unclear precisely how deficits in hypoxanthine and guanine recycling can lead to such a profound neurological phenotype. Several studies have proposed different hypotheses regarding the etiology of this disease, and several treatments have been tried in patients, though none have led to a satisfactory explanation of the disease. New technologies such as next-generation sequencing, optogenetics, genome editing, and induced pluripotent stem cells provide a unique opportunity to map the precise sequential pathways leading from genotype to phenotype.
References
1.
Abel TJ, Dalm BD, Grossbach AJ, Jackson AW, Thomsen T, Greenlee JD: Lateralized effect of pallidal stimulation on self-mutilation in Lesch-Nyhan disease. J Neurosurg Pediatr 14:594-597 (2014).
2.
Afifi AK: Basal ganglia: functional anatomy and physiology. Part 1. J Child Neurol 9:249-260 (1994).
3.
Albert JM, Elie R, Cooper SF, Clermont A, Langlois Y: Efficacy of SCH-12679 in the management of aggressive mental retardates. Curr Ther Res 21:786-795 (1977).
4.
Allen SM, Rice SN: Risperidone antagonism of self-mutilation in a Lesch-Nyhan patient. Prog Neuropsychopharmacol Biol Psychiatry 20:793-800 (1996).
5.
Allen SM, Freeman JN, Davis WM: Evaluation of risperidone in the neonatal 6-hydroxydopamine model of Lesch-Nyhan syndrome. Pharmacol Biochem Behav 59:327-330 (1998).
6.
Bakay B, Nissinen E, Sweetman L, Francke U, Nyhan WL: Utilization of purines by an HPRT variant in an intelligent, nonmutilative patient with features of the Lesch-Nyhan syndrome. Pediatr Res 13:1365-1370 (1979).
7.
Bass CE, Grinevich VP, Vance ZB, Sullivan RP, Bonin KD, Budygin EA: Optogenetic control of striatal dopamine release in rats. J Neurochem 114:1344-1352 (2010).
8.
Bitler CM, Howard BD: Dopamine metabolism in hypoxanthine-guanine phosphoribosyltransferase-deficient variants of PC12 cells. J Neurochem 47:107-112 (1986).
9.
Breese GR, Baumeister AA, McCown TJ, Emerick SG, Frye GD, Mueller RA: Neonatal-6-hydroxydopamine treatment: model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome. Pharmacol Biochem Behav 21:459-461 (1984).
10.
Breese GR, Knapp DJ, Criswell HE, Moy SS, Papadeas ST, Blake BL: The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles. Brain Res Brain Res Rev 48:57-73 (2005).
11.
Castells S, Chakrabarti C, Winsberg BG, Hurwic M, Perel JM, Nyhan WL: Effects of L-5-hydroxytryptophan on monoamine and amino acids turnover in the Lesch-Nyhan syndrome. J Autism Dev Disord 9:95-103 (1979).
12.
Castro Costa MR, Edelstein SB, Castiglione CM, Chao H, Breakefield XO: Properties of monoamine oxidase in control and Lesch-Nyhan fibroblasts. Biochem Genet 18:577-590 (1980).
13.
Catel W, Schmidt J: On familial gouty diathesis associated with cerebral and renal symptoms in a small child (in German). Dtsch Med Wochenschr 84:2145-2147 (1959).
14.
Ceccarelli M, Ciompi ML, Pasero G: Acute renal failure during adenine therapy in Lesch-Nyhan syndrome. Adv Exp Med Biol 41:671-675 (1974).
15.
Chen BC, Balasubramaniam S, McGown IN, OʼNeill JP, Chng GS, et al: Treatment of Lesch-Nyhan disease with S-adenosylmethionine: experience with five young Malaysians, including a girl. Brain Dev 36:593-600 (2014).
16.
Ciaranello RD, Anders TF, Barchas JD, Berger PA, Cann HM: The use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome. Child Psychiatry Hum Dev 7:127-133 (1976).
17.
Cif L, Biolsi B, Gavarini S, Saux A, Robles SG, et al: Antero-ventral internal pallidum stimulation improves behavioral disorders in Lesch-Nyhan disease. Mov Disord 22:2126-2129 (2007).
18.
Connolly GP, Duley JA, Stacey NC: Abnormal development of hypoxanthine-guanine phosphoribosyltransferase-deficient CNS neuroblastoma. Brain Res 918:20-27 (2001).
19.
Cotzias GC: Metabolic modification of some neurologic disorders. JAMA 210:1255-1262 (1969).
20.
Crapper L, Ernst C: Comparative analysis of self-injury in people with psychopathology or neurodevelopmental disorders. Pediatr Clin North Am 62:619-31 (2015).
21.
Criswell HE, Mueller RA, Breese GA: Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors. Eur J Pharmacol 159:141-147 (1989).
22.
Dabrowski E, Smathers SA, Ralstrom CS, Nigro MA, Leleszi JP: Botulinum toxin as a novel treatment for self-mutilation in Lesch-Nyhan syndrome. Dev Med Child Neurol 47:636-639 (2005).
23.
Danjo T, Yoshimi K, Funabiki K, Yawata S, Nakanishi S: Aversive behavior induced by optogenetic inactivation of ventral tegmental area dopamine neurons is mediated by dopamine D2 receptors in the nucleus accumbens. Proc Natl Acad Sci USA 111:6455-6460 (2014).
24.
Deon LL, Kalichman MA, Booth CL, Slavin KV, Gaebler-Spira DJ: Pallidal deep-brain stimulation associated with complete remission of self-injurious behaviors in a patient with Lesch-Nyhan syndrome: a case report. J Child Neurol 27:117-120 (2012).
25.
Devine P: Animal models of self-injurious behaviour: an overview. Methods Mol Biol 829:65-84 (2012).
26.
Di Chiara G, Camba R, Spano PF: Evidence for inhibition by brain serotonin of mouse killing behaviour in rats. Nature 233:272-273 (1971).
27.
Doetschman T, Gregg RG, Maeda N, Hooper ML, Melton DW, et al: Targetted correction of a mutant HPRT gene in mouse embryonic stem cells. Nature 330:576-578 (1987).
28.
Dolcetta D, Parmigiani P, Salmaso L, Bernardelle R, Cesari U, et al: Quantitative evaluation of the clinical effects of S-adenosylmethionine on mood and behavior in Lesch-Nyhan patients. Nucleosides Nucleotides Nucleic Acids 32:174-188 (2013).
29.
Dow LE: Modeling disease in vivo with CRISPR/Cas9. Trends Mol Med 21:609-621 (2015).
30.
Duncan GE, Criswell HE, McCown TJ, Paul IA, Mueller RA, Breese GR: Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine. J Pharmacol Exp Ther 243:1027-1034 (1987).
31.
Elie R, Langlois Y, Cooper SF, Gravel G, Albert JM: Comparison of SCH-12679 and thioridazine in aggressive mental retardates. Can J Psychiatry 25:484-491(1980).
32.
Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, et al: Presynaptic dopaminergic deficits in Lesch-Nyhan disease. N Engl J Med 334:1568-1572 (1996).
33.
Ferrer I, Costell M, Grisolía S: Lesch-Nyhan syndrome-like behavior in rats from caffeine ingestion. FEBS Lett 141:275-278 (1982).
34.
Glick N: Dramatic reduction in self-injury in Lesch-Nyhan disease following S-adenosylmethionine administration. J Inherit Metab Dis 29:687 (2006).
35.
Goldstein M, Anderson LT, Reuben R, Dancis J: Self-mutilation in Lesch-Nyhan disease is caused by dopaminergic denervation. Lancet 1:338-339 (1985).
36.
Goldstein M, Kuga S, Kusano N, Meller E, Dancis J, Schwarcz R: Dopamine agonist induced self-mutilative biting behavior in monkeys with unilateral ventromedial tegmental lesions of the brainstem: possible pharmacological model for Lesch-Nyhan syndrome. Brain Res 367:114-120 (1986).
37.
Gualtieri CT, Schroeder SR: Pharmacotherapy for self-injurious behavior: preliminary tests of the D1 hypothesis. Psychopharmacol Bull 25:364-371 (1989).
38.
Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, et al: Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell 16:269-274 (2015).
39.
Hooper M, Hardy K, Handyside A, Hunter S, Monk M: HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature 326:292-295 (1987).
40.
Hunter TC, Melancon SB, Dallaire L, Taft S, Skopek TR, et al: Germinal HPRT splice donor site mutation results in multiple RNA splicing products in T-lymphocyte cultures. Somat Cell Mol Genet 22:145-150 (1996).
41.
Isotani A, Yamagata K, Okabe M, Ikawa M: Generation of Hprt-disrupted rat through mouse← rat ES chimeras. Sci Rep 6:24215 (2016).
42.
Itil TM, Stock MJ, Duffy AD, Esquenazi A, Saleuty B, Han TH: Therapeutic trials and EEG investigations with SCH-12,679 in behaviorally disturbed adolescents. Curr Ther Res Clin Exp 14:136-150 (1972).
43.
Jankovic J, Caskey TC, Stout JT, Butler IJ: Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol 23:466-469 (1988).
44.
Jeong TS, Lee JH, Kim S, Kim JH, Tootla RG: A preventive approach to oral self-mutilation in Lesch-Nyhan syndrome: a case report. Pediatr Dent 28:341-344 (2006).
45.
Jinnah HA: Lesch-Nyhan disease: from mechanism to model and back again. Dis Model Mech 2:116-121 (2009).
46.
Jinnah HA, Gage FH, Friedmann T: Amphetamine-induced behavioral phenotype in a hypoxanthine-guanine phosphoribosyltransferase-deficient mouse model of Lesch-Nyhan syndrome. Behav Neurosci 105:1004-1012 (1991).
47.
Jinnah HA, Langlais PJ, Friedmann T: Functional analysis of brain dopamine systems in a genetic mouse model of Lesch-Nyhan syndrome. J Pharmacol Exp Ther 263:596-607 (1992).
48.
Jinnah HA, Page T, Friedmann T: Brain purines in a genetic mouse model of Lesch-Nyhan disease. J Neurochem 60:2036-2045 (1993).
49.
Jinnah HA, Yitta S, Drew T, Kim BS, Visser JE, Rothstein JD: Calcium channel activation and self-biting in mice. Proc Natl Acad Sci USA 96:15228-15232 (1999).
50.
Jinnah HA, De Gregorio L, Harris JC, Nyhan WL, O'Neill JP: The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat Res 463:309-326 (2000).
51.
Kang Y, Zheng B, Shen B, Chen Y, Wang L, et al: CRISPR/Cas9-mediated Dax1 knockout in the monkey recapitulates human AHC-HH. Hum Mol Genet 24:7255-7264 (2015).
52.
Kelley WN, Greene ML, Rosenbloom FM, Henderson JF, Seegmiller JE: Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout. Ann Intern Med 70:155-206 (1969).
53.
Khasnavis T, Reiner G, Sommerfeld B, Nyhan WL, Chipkin R, Jinnah HA: A clinical trial of safety and tolerability for the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease. Mol Genet Metab 117:401-406 (2016a).
54.
Khasnavis T, Torres RJ, Sommerfeld B, Puig JG, Chipkin R, Jinnah HA: A double-blind, placebo-controlled, crossover trial of the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease. Mol Genet Metab 118:160-166 (2016b).
55.
Lauber M, Plecko B, Pfiffner M, Nuoffer JM, Häberle J: The effect of S-adenosylmethionine on self-mutilation in a patient with Lesch-Nyhan disease. JIMD Rep, Epub ahead of print (2016).
56.
Lesch M, Nyhan WL: A familial disorder of uric acid metabolism and central nervous system function. Am J Med 36:561-570 (1964).
57.
Lewers JC, Ceballos-Picot I, Shirley TL, Mockel L, Egami K, Jinnah HA: Consequences of impaired purine recycling in dopaminergic neurons. Neuroscience 152:761-772 (2008).
58.
Lloyd KG, Davidson L, Hornykiewicz O: The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 195:453-464 (1975).
59.
Lloyd KG, Hornykiewicz O, Davidson L, Shannak K, Farley I, et al: Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med 305:1106-1111 (1981).
60.
Lubarr N, Bressman S: Treatment of generalized dystonia. Curr Treat Options Neurol 13:274-289 (2011).
61.
Manzke H, Gustmann H, Koke HG, Nyhan WL: Hypoxanthine and tetrahydrobiopterin treatment of a patient with features of the Lesch-Nyhan syndrome. Adv Exp Med Biol 195:197-203 (1986).
62.
Mekhoubad S, Bock C, de Boer AS, Kiskinis E, Meissner A, Eggan K: Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell 10:595-609 (2012).
63.
Mikhailova MA, Bass CE, Grinevich VP, Chappell AM, Deal AL, et al: Optogenetically-induced tonic dopamine release from VTA-nucleus accumbens projections inhibits reward consummatory behaviors. Neuroscience 333:54-64 (2016).
64.
Miocinovic S, Somayajula S, Chitnis S, Vitek JL: History, applications, and mechanisms of deep brain stimulation. JAMA Neurol 70:163-171 (2013).
65.
Mizuno TI, Yugari Y: Letter: Self-mutilation in Lesch-Nyhan syndrome. Lancet 1:761 (1974).
66.
Mizuno I, Yugari Y: Prophylactic effect of L-5-hydroxytryptophan on self-mutilation in the Lesch-Nyhan syndrome. Neuropaediatrie 6:13-23 (1975).
67.
Morris SA: Single-cell RNA-seq steps up to the growth plate. Trends Biotechnol 34:525-527 (2016).
68.
Morton NE, Lalouel JM: Genetic epidemiology of Lesch-Nyhan disease. Am J Hum Genet 29:304-311 (1977).
69.
Moy SS, Knapp DJ, Breese GR: Effect of olanzapine on functional responses from sensitized D1-dopamine receptors in rats with neonatal dopamine loss. Neuropsychopharmacology 25:224-233 (2001).
70.
Moy SS, Fernandes A, Qian Y, Rotella DJ, Kostrewa RM, Breese GR: Effect of acute and chronic olanzapine treatment on phencyclidine-induced behavioral sensitization in rats with neonatal dopamine loss. Pharmacol Biochem Behav 78:47-56 (2004).
71.
Nyhan WL: The recognition of Lesch-Nyhan syndrome as an inborn error of purine metabolism. J Inherit Metab Dis 20:171-178 (1997).
72.
Nyhan WL: Dopamine function in Lesch-Nyhan disease. Environ Health Perspect 108 Suppl 3:409-411 (2000).
73.
Nyhan WL: Lesch-Nyhan disease. J Hist Neurosci 14:1-10 (2005).
74.
Nyhan W, Pesek J, Sweetman L, Carpenter D, Carter C: Genetics of an X-linked disorder of uric acid metabolism and cerebral function. Pediatric Res 1:5-13 (1967).
75.
Nyhan WL, Sweetman L, Carpenter DG, Carter CH, Hoefnagel D: Effects of azathiprine in a disorder of uric acid metabolism and cerebral function. J Pediatr 72:111-118 (1968).
76.
Nyhan WL, Johnson HG, Kaufman IA, Jones KL: Serotonergic approaches to the modification of behavior in the Lesch-Nyhan Syndrome. Appl Res Ment Retard 1:25-40 (1980).
77.
Page T, Nyhan WL: The spectrum of HPRT deficiency: an update. Adv Exp Med Biol 253A:129-133 (1989).
78.
Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, et al: Disease-specific induced pluripotent stem (iPS) cells. Cell 134:877-886 (2008).
79.
Piedimonte F, Andreani JC, Piedimonte L, Micheli F, Graff P, Bacaro V: Remarkable clinical improvement with bilateral globus pallidus internus deep brain stimulation in a case of Lesch-Nyhan disease: five-year follow-up. Neuromodulation 18:118-122 (2015).
80.
Puig JG, Torres RJ, Mateos FA, Ramos TH, Arcas JM, et al: The spectrum of hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency. Clinical experience based on 22 patients from 18 Spanish families. Medicine (Baltimore) 80:102-112 (2001).
81.
Rebai I, Kraoua I, Benrhouma H, Rouissi A, Turki I, et al: Lesch Nyhan syndrome: a novel complex mutation in a Tunisian child. Brain Dev 36:921-923 (2014).
82.
Saito Y, Ito M, Hanaoka S, Ohama E, Akaboshi S, Takashima S: Dopamine receptor upregulation in Lesch-Nyhan syndrome: a postmortem study. Neuropediatrics 30:66-71 (1999).
83.
Schneider SA, Aggarwal A, Bhatt M, Dupont E, Tisch S, et al: Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology 67:940-943 (2006).
84.
Seegmiller JE, Rosenbloom FM, Kelley WN: Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science 155:1682-1684 (1967).
85.
Sege-Peterson K, Chambers J, Page T, Jones OW, Nyhan WL: Characterization of mutations in phenotypic variants of hypoxanthine phosphoribosyltransferase deficiency. Hum Mol Genet 1:427-432 (1992).
86.
Serrano M, Pérez-Dueñas B, Ormazábal A, Artuch R, Campistol J, et al: Levodopa therapy in a Lesch-Nyhan disease patient: pathological, biochemical, neuroimaging, and therapeutic remarks. Mov Disord 23:1297-1300 (2008).
87.
Shirley TL, Lewers JC, Egami K, Majumdar A, Kelly M, et al: A human neuronal tissue culture model for Lesch-Nyhan disease. J Neurochem 101:841-853 (2007).
88.
Silverstein FS, Johnston MV, Hutchinson RJ, Edwards NL: Lesch-Nyhan syndrome: CSF neurotransmitter abnormalities. Neurology 35:907-911 (1985).
89.
Sweetman L, Borden M, Kulovich S, Kaufman I, Nyhan WL: Altered excretion of 5-hydroxyindoleacetic acid and glycine in patients with the Lesch-Nyhan disease, in Müller MM, Kaiser E, Seegmiller JE (eds): Purine Metabolism in Man-II: Regulation of Pathways and Enzyme Defects, pp 398-404 (Springer, Boston 1977).
90.
Taira T, Kobayashi T, Hori T: Disappearance of self-mutilating behavior in a patient with Lesch-Nyhan syndrome after bilateral chronic stimulation of the globus pallidus internus. Case report. J Neurosurg 98:414-416 (2003).
91.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872 (2007).
92.
Torres RJ, Puig JG: Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis 2:48 (2007).
93.
van der Zee SP, Lommen EJ, Trijbels JM, Schretlen ED: The influence of adenine on the clinical features and purine metabolism in the Lesch-Nyhan syndrome. Acta Paediatr Scand 59:259-264 (1970).
94.
Visser JE, Schretlen DJ, Bloem BR, Jinnah HA: Levodopa is not a useful treatment for Lesch-Nyhan disease. Mov Disord 26:746-749 (2011).
95.
Watts RW, McKeran RO, Brown E, Andrews TM, Griffiths MI: Clinical and biochemical studies on treatment of Lesch-Nyhan syndrome. Arch Dis Child 49:693-702 (1974).
96.
Watts RW, Spellacy E, Gibbs DA, Allsop J, McKeran RO, Slavin GE: Clinical, post-mortem, biochemical and therapeutic observations on the Lesch-Nyhan syndrome with particular reference to the Neurological manifestations. Q J Med 51:43-78 (1982).
97.
Wong DF, Harris JC, Naidu S, Yokoi F, Marenco S, et al: Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci USA 93:5539-5543 (1996).
98.
Yamanaka S: Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10:678-684 (2012).
99.
Yeh J, Zheng S, Howard BD: Impaired differentiation of HPRT-deficient dopaminergic neurons: a possible mechanism underlying neuronal dysfunction in Lesch-Nyhan syndrome. J Neurosci Res 53:78-85 (1998).
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
